3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Large B-Cell, Diffuse
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma, Extra-Adrenal
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Osteosarcoma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Gynecological Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Diseases
1
Carcinoma
1
Breast Neoplasms
1
Breast Neoplasm Female
1
Interventions
Ifosfamide
15
Methotrexate
12
Doxorubicin
12
Filgrastim
10
Cisplatin
10
Cyclophosphamide
9
Etoposide
8
Gemcitabine
7
cabozantinib
6
apatinib
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
X-Rays
5
Specimen Handling
5
Sirolimus
5
Phantoms, Imaging
5
Nivolumab
5
Neoadjuvant Therapy
5
camrelizumab
4
Vincristine
4
Topotecan
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Drug Therapy
4
Docetaxel
4
Biopsy
4
regorafenib
3
palbociclib
3
olaparib
3
mifamurtide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Osteosarcoma
×
penpulimab
×
Clear all
NCT06114225
2023-11-02
PROMIS
Ruijin Hospital
Phase 2
Recruiting
43 enrolled